Structure Therapeutics (GPCR) Cash from Operations (2022 - 2026)

Structure Therapeutics' Cash from Operations history runs 5 years deep, the most recent figure standing at 15234000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 129.17% year-over-year to 15234000.0; the TTM figure through Mar 2026 stood at 154736000.0 (down 14.8% YoY), while the FY2025 annual figure was 222199000.0, down 90.51% from the prior year.
• Cash from Operations was 15234000.0 for Q1 2026 at Structure Therapeutics, up from 64416000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 15234000.0 in Q1 2026 to a low of 64416000.0 in Q4 2025.
• Historically, Cash from Operations has averaged 26424058.82 across 5 years, with a median of 20557000.0 in 2023.
• The sharpest annual moves came in 2025 and 2026: Cash from Operations plunged 158.92% in 2025, then surged 129.17% in 2026.
• A 5-year view of Cash from Operations shows it stood at 12026000.0 in 2022, then tumbled by 80.68% to 21729000.0 in 2023, then tumbled by 67.83% to 36467000.0 in 2024, then plunged by 76.64% to 64416000.0 in 2025, then soared by 123.65% to 15234000.0 in 2026.
• The last three Cash from Operations figures came in at 15234000.0 (Q1 2026), 64416000.0 (Q4 2025), and 50996000.0 (Q3 2025), per Business Quant data.